# Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

> **NCT07572136** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 57 (estimated)

## Conditions studied

- B-All
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** TSLPR-CART
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07572136
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2030-06-30
- **Final completion:** 2032-06-30
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07572136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07572136, "Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07572136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*